Menu Display

Breadcrumb

Media

U.S. News Room

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

February 24, 2021
Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma Download
February 22, 2021
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D Download
February 17, 2021
New Survey Reveals Nearly Half of Women Are Unfamiliar with a Condition that Affects Up to Five Million Adults in the U.S. Download
February 03, 2021
HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC Download
February 02, 2021
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute Download
January 29, 2021
​​​​​​​New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented at WCLC 2020 Download
January 29, 2021
Datopotamab Deruxtecan and ENHERTU® Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer Download
January 27, 2021
ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society Download
January 15, 2021
ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive Advanced Gastric Cancer   Download
January 13, 2021
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung Cancer
ENHERTU Plus Pertuzumab Approved in the US as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Page 10 of 10
20 Items per Page
Showing 181 - 191 of 191 results.